UBS has issued fresh rankings for fertilizer stocks, placing nitrogen-centric businesses ahead of potash and phosphate peers for expected near-term performance heading into 2027. The bank points to a combination of returning demand, persistent Middle East supply interruptions and elevated European natural gas prices as the principal drivers that support the nitrogen cost curve and underlying pricing.
Nitrogen seen as the sector leader
According to UBS, producers focused on nitrogen are best situated to benefit from what the bank describes as a compressed demand timetable paired with ongoing supply constraints. UBS expects these factors to translate into stronger pricing into the spring peak demand season. The analysts caution, however, that heightened Chinese exports and softer ammonia markets remain headwinds, though they still view prevailing price levels as unsustainably discounted relative to the cost curve.
Across its fertilizer coverage UBS raised 2027 and 2028 estimates, with the most significant increases attributed to the improving nitrogen outlook.
Company-by-company takeaways
1. CF Industries - Neutral
UBS identifies CF Industries as the primary beneficiary of a strengthening nitrogen backdrop, characterizing it as a pure-play nitrogen producer. The bank lifted its 2027 and 2028 estimates for CF by 24% and 16% respectively. Those revised projections place UBS's expectations about 34% above consensus for one year and roughly 1% below consensus for the next.
UBS's modeling implies a valuation for CF toward the mid-$130 range, while noting the stock has already traded up into the low $120s. The bank also notes CF has oscillated between roughly $100 and $140 per share multiple times this year and expects continued volatility tied to developments around Middle East reopening news.
2. Nutrien - Sell
Nutrien is ranked second by UBS but is considered to capture less upside from nitrogen improvement because of its diversified mix - exposure to potash, nitrogen and retail operations dampens its pure-play nitrogen leverage. UBS observed that potash pricing held up better than expected through a seasonally weak third quarter, supporting a stronger exit rate into the fourth quarter.
UBS increased its 2027 and 2028 EBITDA estimates for Nutrien by 10% and 3% respectively. Those revised forecasts are now about 3% above consensus for 2027 and roughly 4% below consensus for 2028. Despite these adjustments, UBS continues to flag medium-term oversupply risk for potash as approximately 15 million metric tons of new capacity is scheduled to come online through 2030, with potential implications from mid-2027 onward.
3. The Mosaic Company - Neutral
UBS places Mosaic third and describes it as facing the most difficult near-term outlook among the covered names due to disruptions in phosphate markets. While UBS noted a modestly improved potash outlook into the first half of 2027, phosphate markets remain under pressure because of Middle East disruptions to sulfur supply, which has severely curtailed global phosphate operating rates. UBS cites estimates that around 50% of global phosphate production is currently offline.
Mosaic's stock has declined from roughly $26 to near $18 per share recently. UBS raised its 2027 and 2028 estimates for Mosaic by 9% and 5%, but these revised figures still sit about 21% and 1% below consensus, respectively, on the assumption that phosphate markets begin to normalize in the second quarter of 2027.
Implications for markets and participants
UBS's repositioning underscores how input-cost dynamics - notably European natural gas prices - and regional supply interruptions can quickly shift relative attractiveness across fertilizer subsectors. Producers with concentrated nitrogen exposure may see outsized upside if the bank's assumption of tighter supply and returning spring demand holds. Conversely, diversified businesses or those exposed to phosphate are portrayed as facing larger structural challenges in the near term.